Drug intelligence / Profile preview

NeuGcGM3 + VSSP + Montanide ISA 51

Development stage: Preclinical
Lead developer: Center for Molecular Immunology
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

NeuGcGM3 + VSSP + Montanide ISA 51 is a combination therapeutic cancer vaccine. It combines the NeuGcGM3 antigen with VSSP (Very Small Size Proteoliposomes) as an immunostimulant and Montanide ISA 51 as an adjuvant. Montanide ISA 51 is a vaccine adjuvant that creates a depot effect at the injection site, allowing slow and prolonged release of antigens. This formulation enhances CD4+ and CD8+ T cell responses and amplifies antibody production specific to cancer antigens. The combination is designed to stimulate the immune system against cancer cells expressing the NeuGcGM3 ganglioside.

Targets

NeuGcGM3 (N-glycolyl-GM3 ganglioside)

Beyond the preview

Go deeper on NeuGcGM3 + VSSP + Montanide ISA 51.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuGcGM3 + VSSP + Montanide ISA 51.

Explore the full profile